Zocere Names Former Glaxo Pharma Exec Adrian Hobden to Board

  Zocere Names Former Glaxo Pharma Exec Adrian Hobden to Board

Business Wire

ALBUQUERQUE, N.M. -- January 30, 2014

New Mexico-based pharmaceutical company Zocere, Inc. has named former
pharmaceutical executive Adrian Hobden, Ph.D., to its Board of Directors.
Hobden has been instrumental in developing and commercializing pharmaceuticals
for a range of disease areas, including cancer, Alzheimer’s disease,
cardiovascular, respiratory, HIV, and antifungals.

Zocere is developing an injectable drug designed to protect patients from
brain injury by arresting the progression of brain damage caused by reduced
blood flow. While the initial target is stroke, Zocere’s drug shows promise in
treating other brain trauma such as concussion. The human STEP peptide-based
drug is being licensed from STC.UNM and was developed at the University of New
Mexico.

Hobden brings a wealth of experience to the Zocere Board based upon a long and
distinguished career in the global pharmaceutical industry. He joined Glaxo in
the United Kingdom (U.K.) as a research scientist in 1981 and went on to run
its Genetics Department and several others, including CNS Pharmacology. Hobden
moved to the United States in 1996 and was responsible for Glaxo’s
collaborations with biotechnology companies. In 1998, he joined Myriad
Genetics in Salt Lake City as president of Myriad Pharmaceuticals. This
division was later spun out as a public company called Myrexis with Hobden as
CEO. He retired from Myrexis in 2011.

Commenting on Hobden’s board appointment, Zocere President and CEO Wayne
Laslie said, “I have known Adrian for many years and have a deep respect for
his ability to advance promising compounds through the commercialization
process. We welcome his knowledge and counsel as we work to commercialize this
and other neuroprotectant compounds.”

Hobden earned his Bachelor’s and Master’s degrees in Biochemistry from
Cambridge University and a Ph.D. in Molecular Biology from Leicester
University, both in the U.K. He also completed a postdoctoral fellowship with
the Medical Research Council in the U.K. In addition to the Zocere Board,
Hobden serves on the Board of Directors of the Hope Fund for Cancer Research.

About Zocere, Inc.

Headquartered in Albuquerque, New Mexico, Zocere is a startup pharmaceutical
company developing injectable, neuroprotectant drugs intended to combat stroke
and other neurological trauma. Zocere is led by a team of seasoned
pharmaceutical industry executives with extensive experience in drug
commercialization. Visit www.Zocere.com.

Contact:

Lux + Associates
Melanie Lux, 803-331-4794
mlux@luxandassociates.com
 
Press spacebar to pause and continue. Press esc to stop.